T-CELL PROLYMPHOCYTIC LEUKEMIA
Clinical trials for T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. About 70 participants will receive the drugs to find the best dose and see if the combination can co…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope: drug may stop lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC